DelveInsight has launched a new report on Anemia In Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anemia is a frequent complication of chronic kidney disease (CKD) and it is associated with a decrease in the quality of life of patients, it causes an increase in morbidity and mortality and accelerates the rate of progression of CKD. In patients with CKD, anemia is defined as the situation in which the concentration of hemoglobin (Hb) in the blood is below 2 times the SD of the mean Hg of the general population, corrected for age and sex.
The main cause of anemia in CKD is the inadequate production of endogenous erythropoietin, a hormone that acts on the differentiation and maturation of the red blood cells precursors. Other contributing factors have been recognized in recent years as a impaired response of the bone marrow to erythropoietin caused by uremic toxins, inflammation, decreased availability of iron for erythropoiesis and increased levels of hepcidin, a shortened of red blood cells (RBC) half-life or vitamin deficiencies (vitamin B12 or folic acid), among others.
Request for :- Anemia In Chronic Kidney Disease free sample page
Anemia In Chronic Kidney Disease Epidemiology
The Anemia In Chronic Kidney Disease epidemiology division provide insights about historical and current Anemia In Chronic Kidney Disease patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Report Key Facts:-
1. According to NHANES survey, the prevalence of anemia increased with stage of CKD, from 8.4% at stage 1 to 53.4% at stage 5. A total of 22.8% of CKD patients with anemia reported being treated for anemia within the previous 3 months–14.6% of patients at CKD stages 1–2 and 26.4% of patients at stages 3–4.
2. According to the study conducted by Steven F. et al. 2018, in patients with stage 3 CKD, 22.2% of patients with diabetes were anemic, increasing to 52.4% in stage 4 CKD.
Report Key Benefits :-
1. Anemia In Chronic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Anemia In Chronic Kidney Disease epidemiology Anemia In Chronic Kidney Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Anemia In Chronic Kidney Disease market report provides insights on the current and emerging therapies.
3. Anemia In Chronic Kidney Disease market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. Anemia In Chronic Kidney Disease market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market.
“According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Anemia commonly occurs in people with chronic kidney disease (CKD) which results into permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD, when someone has 20 to 50 percent of normal kidney function. Anemia tends to worsen as CKD progresses. Most people who have total loss of kidney function, or kidney failure, have anemia.”
Key companies working on Anemia In Chronic Kidney Disease are given below:-
1. Vifor Pharma Co.
2. Astellas Pharma/FibroGen
Covered Drugs are given below:-
1. Mircera
2. Evrenzo
Table of Contents
1. Key Insights
2. Executive Summary of Anemia In Chronic Kidney Disease
3. Competitive Intelligence Analysis for Anemia In Chronic Kidney Disease
4. Anemia In Chronic Kidney Disease: Market Overview at a Glance
5. Anemia In Chronic Kidney Disease: Disease Background and Overview
6. Patient Journey
7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Anemia In Chronic Kidney Disease Treatment
11. Marketed Products
12. Emerging Therapies
13. Anemia In Chronic Kidney Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Anemia In Chronic Kidney Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this Anemia In Chronic Kidney Disease market report?
Related Reports :-
1. Anemia In Chronic Kidney Disease Epidemiology Forecast to 2030
2. Anemia In Chronic Kidney Disease Pipeline Insights, 2020
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/